| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Parallel Industries Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 0% |
| 3 Year Change | -99.93% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| EAPH | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -2.2% | -3.7% |
| 1Y | 0% | 11.6% | 20.5% |
Return vs Industry: EAPH underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: EAPH underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| EAPH volatility | |
|---|---|
| EAPH Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: EAPH's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine EAPH's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | n/a | Evan Karras | www.eastonpharma.com |
Parallel Industries Inc. does not have significant operations. Previously, the company was involved in development and markets various topically delivered drugs to treat cancer and other therapeutic products to treat various conditions. It focuses on development, licenses, production, and markets prescription and over-the-counter products.
Parallel Industries Inc. Fundamentals Summary
| EAPH fundamental statistics | |
|---|---|
| Market cap | US$1.34k |
| Earnings (TTM) | -US$188.54k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs EAPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EAPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$188.54k |
| Earnings | -US$188.54k |
Last Reported Earnings
Dec 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did EAPH perform over the long term?
See historical performance and comparison